Beximco Pharmaceuticals Limited has launched bird flu drug, Oseflu, in Myanmar for the prevention and treatment of human cases of Avian influenza.

“We’ll be exporting 2,000 doses of the drug to Myanmar very soon,” chief executive officer of Beximco Pharma Nazmul Hassan said at the launch, adding that the company was in the process of registering the drug in many other countries.

The drug was registered with the Myanmar Food and Drug Administration (FDA) under the Health Ministry of the country on May 24, said a corporate release Wednesday.

Avian influenza has been detected on a large scale in Myanmar.

Oseflu, the only Oseltamivir Brand from Bangladesh to get registration in any overseas market, was launched in Myanmar in the first week of this month.

Around 500 front-line physicians of Myanmar and distinguished guests from Ministry of Health of Myanmar, WHO, UNICEF, UNDP, CARE, Myanmar Medical Association (MMA) and high officials of Bangladesh Embassy in Myanmar were present at the launch ceremony in Yangon on Sunday.

“It’s a great relief for us,” a leading physician of Myanmar, Professor Dr. Soe Lwin Nyein said, as Myanmar physicians were anxious about getting adequate amount of Oseltamivir at a reasonable price on the first outbreak of the virus.

Besides the launch ceremony, a scientific symposium on Avian Influenza was also held on the occasion.

Earlier, in March this year, when the first case of bird flu was reported in Myanmar, Beximco Pharma, as a gesture of goodwill, donated 100 doses of Oseflu to the Health Ministry of Myanmar.